Fig. 2 | Scientific Reports

Fig. 2

From: Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients

Fig. 2

RBD-ACE2 blocking antibody (A), anti-spike antibody (B), and anti-RBD IgG antibody levels (C) in CoronaVac-vaccinated individuals. Blocking antibodies against ancestral SARS-CoV-2 and 12 non-Omicron and Omicron variants were determined using multiplex sVNT assay. Anti-spike antibodies were measured using the Elecsys® anti-spike assay, and anti-RBD IgG antibodies against RBD of the Delta variant were determined using in-house ELISA. A negative result for nAbs was defined as a percent inhibition lower than 30% (indicated by the dotted red line), whereas a negative result for anti-spike antibodies was defined a level lower than 0.8 U/ml. The Kruksall-Wallis test with Dunn’s multiple comparison test was used to assess differences between groups. Data of anti-RBD IgG levels were obtained from20.

Back to article page